Pathstone Holdings LLC Has $6.98 Million Stock Position in STERIS plc (NYSE:STE)

Pathstone Holdings LLC lessened its stake in shares of STERIS plc (NYSE:STE - Free Report) by 5.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 33,918 shares of the medical equipment provider's stock after selling 1,957 shares during the quarter. Pathstone Holdings LLC's holdings in STERIS were worth $6,976,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in STERIS by 30.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,970 shares of the medical equipment provider's stock worth $2,275,000 after purchasing an additional 2,583 shares in the last quarter. Merit Financial Group LLC acquired a new position in shares of STERIS in the fourth quarter valued at approximately $260,000. Blue Trust Inc. raised its holdings in STERIS by 19.9% in the 4th quarter. Blue Trust Inc. now owns 1,128 shares of the medical equipment provider's stock valued at $232,000 after buying an additional 187 shares during the last quarter. Entropy Technologies LP acquired a new stake in STERIS during the 4th quarter worth approximately $924,000. Finally, Park Avenue Securities LLC boosted its position in STERIS by 5.6% during the 4th quarter. Park Avenue Securities LLC now owns 2,369 shares of the medical equipment provider's stock worth $487,000 after buying an additional 126 shares during the period. 94.69% of the stock is currently owned by institutional investors and hedge funds.

STERIS Trading Down 0.3%

STE traded down $0.74 during trading on Friday, reaching $243.07. 157,200 shares of the stock traded hands, compared to its average volume of 542,424. The company has a quick ratio of 1.40, a current ratio of 2.13 and a debt-to-equity ratio of 0.32. The stock's 50-day moving average is $225.95 and its 200 day moving average is $220.00. STERIS plc has a 12 month low of $200.98 and a 12 month high of $252.79. The stock has a market capitalization of $23.88 billion, a PE ratio of 51.64 and a beta of 0.96.

STERIS (NYSE:STE - Get Free Report) last announced its earnings results on Wednesday, May 14th. The medical equipment provider reported $2.74 EPS for the quarter, beating the consensus estimate of $2.59 by $0.15. The company had revenue of $1.48 billion for the quarter, compared to analyst estimates of $1.47 billion. STERIS had a return on equity of 13.91% and a net margin of 8.66%. The firm's revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.58 EPS. Equities analysts anticipate that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 26th. Stockholders of record on Tuesday, June 10th will be given a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 0.94%. The ex-dividend date is Tuesday, June 10th. STERIS's dividend payout ratio (DPR) is 36.77%.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Morgan Stanley upped their price target on shares of STERIS from $240.00 to $260.00 and gave the company an "equal weight" rating in a research report on Monday. Citigroup restated an "outperform" rating on shares of STERIS in a report on Friday, May 16th. Needham & Company LLC reaffirmed a "hold" rating on shares of STERIS in a report on Monday, April 7th. Wall Street Zen raised STERIS from a "buy" rating to a "strong-buy" rating in a research note on Thursday. Finally, JMP Securities raised their price objective on STERIS from $265.00 to $280.00 and gave the stock a "market outperform" rating in a research report on Friday, May 16th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, STERIS has a consensus rating of "Moderate Buy" and an average target price of $264.00.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.